If you find this podcast useful please give it a rating and review on iTunes by clicking here
Neil Clark, CEO & Shaun Claydon, CFO of Destiny Pharma discuss their final results & post period highlights, which included a deal on their lead asset, NTCD-M3, worth up to $570m plus royalties. Neil also points out that the number one target for the company this year is landing a deal on their second late stage asset, XF-73.
Highlights
- Exclusive North American partnering deal worth up to $570m plus royalties secured for NTCD-M3
- Phase 3 development plans finalised for XF-73 nasal following scientific advice from FDA and EMA
- XF-73 dermal commenced clinically enabling safety study sponsored by US Government's NIAID
- New XF research projects initiated in cystic fibrosis and oral mucositis
- Leadership strengthened with appointment of Chief Medical Officer and two Non-Executive Directors
- Balance sheet strengthened through £7.3 million fundraise post period end